Therefore, in the Phase 3 study CEL-SCI treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with Multikine
first, BEFORE they receive surgery, radiation and/or chemotherapy.
We believe the following developments with regard to the Multikine* Phase 3 trial have contributed to additional investments in our Company: We have not yet hit the primary endpoint of our 928 patient Phase 3 study with our investigational cancer immunotherapy drug Multikine
. That endpoint will be reached when 298 events (deaths) have occurred and are recorded in the two main comparator arms of the study.
It fortified its patent portfolio with three new patents for LEAPS and Multikine
. It has raised approximately USD21.4m in gross proceeds through the sale of stock and the exercise of warrants.
(Leukocyte interleukin, CEL-SCI): What do KOLS say CEL-SCI can do to increase Multikine
's chances for success?
CEL-SCI Corporation (NYSE MKT: CVM) has released a new video about its investigational cancer drug Multikine
and the dedicated manufacturing facility to produce Multikine
near Baltimore, MD, USA.
The company plans to use the proceeds from the transaction to back its Phase III clinical trial with its investigational cancer drug Multikine
(Leukocyte Interleukin, Injection), as well as for general and administrative expenses.
Its lead product is Multikine
which is currently being readied for a global Phase III trial.
(Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for the neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
While we do not like waiting, we also recognize that this may be a positive development for our Phase 3 study since Multikine
may be the reason for not yet having reached 298 events.
M2 EQUITYBITES-August 17, 2017-USFDA removes clinical hold on Multikine
's phase three cancer study
The money raised from the sale of stock and warrants will be used in support of the company's Phase III clinical studies with its investigational cancer drug Multikine
(Leukocyte Interleukin, Injection).
The company has received the go-ahead from the United States FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine
. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with United States government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu.